Dopamine D2 Receptor Levels in Striatum, Thalamus, Substantia Nigra, Limbic Regions, and Cortex in Schizophrenic Subjects

Biological Psychiatry

Volumn 65, Issue 12, 2009, Pages 1024-1031

  Kessler, Robert M ^a   Woodward, Neil D ^a   Riccardi, Patrizia ^a   Li, Rui ^a   Ansari, M Sib ^a   Anderson, Sharlett ^a   Dawant, Benoit ^a   Zald, David ^a   Meltzer, Herbert Y ^a  

^a VANDERBILT UNIVERSITY   (United States)

Author keywords

Delusions; dopamine D2 receptors; fallypride; hallucinations; schizophrenia; substantia nigra; thalamus

Indexed keywords

DOPAMINE 2 RECEPTOR; BENZAMIDE DERIVATIVE; DIAGNOSTIC AGENT; N ((1 ALLYL 2 PYRROLIDINYL)METHYL) 5 (3 FLUOROPROPYL) 2,3 DIMETHOXYBENZAMIDE; N-((1-ALLYL-2-PYRROLIDINYL)METHYL)-5-(3-FLUOROPROPYL)-2,3-DIMETHOXYBENZAMIDE; PYRROLIDINE DERIVATIVE; RADIOPHARMACEUTICAL AGENT;

ADULT; ARTICLE; BRAIN CORTEX; CINGULATE GYRUS; CONTROLLED STUDY; CORPUS STRIATUM; DELUSIONAL DISORDER; FEMALE; HUMAN; IMAGE ANALYSIS; LIMBIC CORTEX; MAJOR CLINICAL STUDY; MALE; NEUROTRANSMISSION; PATIENT SELECTION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN FUNCTION; SCHIZOPHRENIA; SUBSTANTIA NIGRA; TEMPORAL CORTEX; THALAMUS; THINKING IMPAIRMENT; TISSUE LEVEL; BIOSYNTHESIS; BRAIN LEVEL; IMAGE PROCESSING; LIMBIC SYSTEM; METABOLISM; MIDDLE AGED; NEOSTRIATUM; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSIOLOGY; SCINTISCANNING; STATISTICAL ANALYSIS;

ADULT; BENZAMIDES; BRAIN CHEMISTRY; CEREBRAL CORTEX; DATA INTERPRETATION, STATISTICAL; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; LIMBIC SYSTEM; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOSTRIATUM; POSITRON-EMISSION TOMOGRAPHY; PYRROLIDINES; RADIOPHARMACEUTICALS; RECEPTORS, DOPAMINE D2; SCHIZOPHRENIA; SUBSTANTIA NIGRA; THALAMUS; YOUNG ADULT;

EID: 67349219375     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopsych.2008.12.029     Document Type: Article

References (88)

1. Davis K.L., Kahn R.S., Ko G., and Davidson M. Dopamine in schizophrenia: A review and reconceptualization. Am J Psychiatr 148 (1991) 1474-1486
2. Weinberger D.R., Egan M.F., Bertolino A., Callicott J.H., Mattay V.S., Lipska B.K., et al. Prefrontal neurons and the genetics of schizophrenia. Biol Psychiatry 50 (2001) 825-844
3. Daniel D.G., Weinberger D.R., Jones D.W., Zigun J.R., Coppola R., Handel S., et al. The effect of amphetamine on regional cerebral blood flow during cognitive activation in schizophrenia. Neurosci 11 (1991) 1907-1917
4. Lewis D.A., and Gonzlaex-Burgos G. Neuroplasticity of neocortical circuits in schizophrenia. Neuropsychopharmacology 33 (2008) 141-165
5. Bilder R.M., Reiter G., Bates J., Lencz T., Szeszko P., Goldman R.S., et al. Cognitive development in schizophrenia: Follow-back from the first episode. J Clin Exp Neuropsychol 28 (2006) 270-282
6. Lewis D.A., Hashimoto T., and Volk D.W. Cortical inhibitory neurons and schizophrenia. Neuroscience 6 (2005) 312-324
7. Sesack S.R., and Pickel V.M. Prefrontal cortical efferents in the rat synapse on unlabeled neuronal targets of catecholamine terminals in the nucleus accumbens septi and on dopamine neurons in the ventral tegmental area. J Comp Neurol 8 320 (1992) 145-160
8. Deutch A.Y. The regulation of subcortical dopamine systems by the prefrontal cortex: Interactions of central dopamine systems and the pathogenesis of schizophrenia. J Neural Transm Suppl 36 (1992) 61-89
9. Taber M.T., Das S., and Fibiger H.C. Cortical regulation of subcortical dopamine release: mediation via the ventral tegmental area. J Neurochem 65 (1995) 1407-1410
10. Harden D.G., King D., Finlay J.M., and Grace A.A. Depletion of dopamine in the prefrontal cortex decreases the basal electrophysiological activity of mesolimbic dopamine neurons. Brain Res 794 (1998) 96-102
11. Laruelle M., Abi-Dargham A., van Dyck C.H., Gil R., D'Souza C.D., Erdos J., et al. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci U S A 93 (1996) 9235-9240
12. Sesack S.R., and Carr D.B. Selective prefrontal cortex inputs to dopamine cells: Implications for schizophrenia. Physiol Behav 77 (2002) 513-517
13. Khan Z.U., Gutiérrez A., Martín R., Peňafiel A., Rivera A., and DeLa Calle A. Differential regional and cellular distribution of dopamine D2- like receptors: An immunocytochemical study of subtype- specific antibodies in rat and human brain. J Comp Neurol 402 (1998) 353-371
14. Tseng K.Y., and O'Donnell P. Dopamine-glutamate interactions controlling prefrontal cortical pyrmidal cell excitability involve multiple signaling mechanisms 24 (2004) 5131-5139
15. Sesack S.R., Aoki C., and Pickel V.M. Ultrastructural localization of D2 receptor- like immunoreactivity in midbrain dopamine neurons and their striatal targets. J Neurosci 14 (1994) 88-106
16. Cragg S.J., and Greenfield S.A. Differential autoreceptor control of somatodendritic and axon terminal dopamine release in substantia nigra, ventral tegmental area, and striatum. J Neurosci 17 (1997) 5738-5746
17. Wolf M.E., and Roth R.H. Autoreceptor regulation of dopamine synthesis 604 (1990) 323-343
18. Akil M., Edgar C.L., Pierri J.N., Whitehead R.E., Edgar C.L., Mohila C., et al. Lamina-specific alterations in the dopamine innervation of the prefrontal cortex in schizophrenic subjects. Am J Psychiatry 156 (1999) 1580-1589
19. Akil M., Edgar C.L., Pierri J.N., Casali S., and Lewis D.A. Decreased density of tyrosine hydroxylase-immunoreactive axons in the enthorhinal cortex of schizophrenic subjects. Biol Psychiatry 47 (2000) 361-370
20. Benes F.M., and Todtenkopf M.S. Effect of age and neuroleptics on tyrosine hydroxylase- IR in sector CA2 of schizophrenic brain. Neuroreport 10 (1999) 3527-3530
21. Wyatt R.J., Karoum F., and Casanova M.F. Decreased DOPAC in the anterior cingulate cortex of individuals with schizophrenia. Biol Psychiatry 38 (1995) 4-12
22. 2 receptor binding in the anterior cingulate cortex in schizophrenia. Arch Gen Psychiatry 59 (2002) 25-30
23. Tuppurainen H., Kuikka J., viinamäki H., Husso-Saastamoinen M., Bergstrom K., and Tiihonen J. Extrastriatal dopamine D 2/3 receptor density and distribution in drug-naive schizophrenic patients. Mol Psychiatry 8 (2003) 453-455
24. 11C] FLB 457. Intl J Neuropsychopharm 6 (2003) 361 170
25. 2 receptor binding in subregions of the thalamus in schizophrenia. Am J Psychiatry 161 (2004) 1016-1022
26. Buchsbaum M.S., Christian B.T., Lehrer D.S., Narayanan T.K., Shi B., Mantil J., et al. D2/D3 dopamine receptor binding with [F-18] fallypride in thalamus and cortex of patients with schizophrenia. Schizophr Res 85 (2006) 232-244
27. 2/3 receptor binding in drug-naïve first-episode schizophrenic patients correlates with positive psychotic symptoms and gender. Biol Psychiatry 60 (2006) 621-629
28. Abi-Dargham A., Mawlawi O., Lombardo I., Gil R., Martinez D., Huang Y., et al. Prefrontal dopamine D1 receptors and working memory in schizophrenia. J Neurosci 22 (2002) 3708-3719
29. Okubo Y., Suhara T., Kobayashi K., Inoue O., Terasaki O., Someya Y., et al. Decreased prefrontal dopamine D1 receptors in Schizophrenia revealed by PET. Nature 385 (1997) 634-636
30. Karlsson P., Farde L., Halldin C., and Sedvall G. PET study of D(1) dopamine receptor binding in neuroleptic-naive patients with schizophrenia. Am J Psychiatry 159 (2002) 761-767
31. Toru M., Watanabe S., Shibuya H., Nishikawa T., Noda K., Mitsushio H., et al. Neurotransmitters, receptors and neuropeptides in post-mortem brains of chronic schizophrenic patients. Acta Psychiatr Scand 78 (1988) 121-137
32. Mueller H.T., Haroutunian V., Davis K.L., and Meador-Woodruff J.H. Expression of the ionotropic glutamate receptor subunits and NMDA receptor-associated intracellular proteins in the substantia nigra in schizophrenia. Brain Res Mol Brain Res 121 (2004) 60-69
33. 2 receptors in substantia nigra in schizophrenia. Brain Res 299 (1984) 152-154
34. Laruelle M., Abi-Dargham A., Gil R., Kegeles L., and Innis R. Increased dopamine transmission in schizophrenia: Relationship to illness phases. Biol Psychiatry 46 (1999) 56-72
35. Breier A., SU T.P., Saunders R., Carson R.E., Kolachana B.S., Bartolomeis A., et al. Schizophrenia is associated with elevated amphetamine- induced synaptic dopamine concentrations. Proc Nat Acad Sci U S A 94 (1997) 2569-2574
36. 2 receptors by dopamine in schizophrenia. Proc Natl Acad Sci U S A 97 (2000) 8104-8109
37. Bird E.D., Spokes E.G.S., and Iversen L.L. Increased dopamine concentration in limbic areas of brain from limbic areas of brain from patients dying with schizophrenia. Brain 102 (1979) 347-360
38. Mackay A.V., Iversen L.L., Rossor M., Spokes E., Bird E., Arregui A., et al. Increased brain dopamine and dopamine receptors in schizophrenia. Arch Gen Psychiatry 39 (1982) 991-996
39. Reith J., Benkelfat C., Sherwin A., Yasuhara Y., Kuwabara H., Andermann F., et al. Elevated dopa decarboxylase activity in living brain of patients with psychosis. Proc Natl Acad Sci U S A 91 (1994) 11651-11654
40. Hietala J., Syvälahti E., Vuorio K., Räkköläinen V., Bergman J., Haaparanta M., et al. Presynaptic dopamine function in striatum of neuroleptic-naïve schizophrenic patients. Lancet 346 (1995) 1130-1131
41. 18F- DOPA PET study in patients with schizophrenia. Psychiatry Res 100 (2000) 1-11
42. Seeman P., Ulpian C., Bergeron C., Riederer P., Jellinger K., Gabriel E., et al. Bimodal Distribution of dopamine receptor densities in brains of schizophrenics. Science 225 (1984) 728-731
43. Seeman P., Bzowej N.H., Guan H.C., Bergeron C., Reynolds G.P., Bird E.D., et al. Human brain D1 and D2 dopamine receptors in schizophrenia, Alzheimer's, Parkinson's, and Huntington's diseases. Neuropsychopharmacology 1 (1987) 5-15
44. 2dopamine receptors in neuroleptic-naïve schizophrenic patients. Arch Gen Psychiatry 47 (1990) 213-219
45. Hietala J., Syvälahtti E., Vuorio K., Någren K., Lehikoinen P., Ruotsalainen U., et al. Striatal D2 dopamine receptor characteristics in neuroleptic-naïve schizophrenic patients studied with positron emission tomography. Arch Gen Psychiatry 51 (1994) 116-123
46. Wong D.F., Wagner Jr. H.N., Tune L.E., Dannals R.F., Pearlson G.D., Links J.M., et al. Positron emission tomography reveals elevated D2 dopamine receptors in drug-naïve schizophrenics. Science 234 (1986) 155-163
47. 18F] N-allyl-5-fluoropropylepidepride (fallypride): radiation dosimetry, quantification of striatal and extrastriatal dopamine receptors in man. NeuroImage 11 6 (2000) S32
48. 18F- fallypride in normal volunteers: blood analysis, distribution, test-retest studies, and preliminary assessment of sensitivity to aging effects on dopamine D-2/D-3 receptors. Synapse 46 (2002) 170-188
49. 18F] fallypride. Biol Psychiatry 63 (2008) 241-244
50. Andreasen N.C., Endicott J., Spitzer R.L., and Winokur G. The family history method using diagnostic criteria. Reliability and validity. Arch Gen Psychiatry 34 (1977) 1229-1235
51. First M.B., Spitzer R.I., Gibbon M., and Williams J.B.W. Structured Clinical Interview for Axis I DSM- IV Disorders-Patient Edition (with psychotic Screen) (SCID-I/P) (Version 2.0) (1996), Biometrics Research Department, New York State Psychiatric Institute, New York
52. Maes F., Collognon A., Vandermuele D., Marchal G., and Suetens P. Multimodality image registration by maximization of mutual information. IEEE Trans Med Imaging 16 (1997) 187-198
53. Wells W.M., Viola P., Atsumi H., Nakajima S., and Kikinis R. Multimodal volume registration by maximization of mutual information. Med Img Anal 1 (1996) 35-51
54. Mawlawi O., Martinez D., Slifstein M., Broft A., Chatterjee R., Hwang D.R., et al. Imaging human mesolimbic dopamine transmission with positron emission tomography: I. Accuracy and precision of D (2) receptor parameter measurements in ventral striatum. J Cereb Blood Flow Metab 21 (2001) 1034-1057
55. Byne W., Buchsbaum M.S., Hazlett E.A., Kemether E., Shinwari A., Mitropoulou V., and Siever L.J. Magnetic resonance imaging of the thalamic mediodorsal nucxleus and pulvinar in schizophrenia and schizotypal personality disorder. Arch Gen Psychiatry 58 (2001) 133-140
56. Schaltenbrand G., and Wahren W. Atlas for Stereotaxy of the Human Brain (1977), Yearbook Medical Publisher, Chicago
57. 18F] fallypride in striatum and extrastriatal regions in humans. Neuropsychopharmacology 31 (2006) 1016-1026
58. 11C] raclopride studies. J Cereb Blood Flow Metab 16 (1996) 42-52
59. Kessler R.M., Ansari M.S., Riccardi P., Li R., Jayathilake K., Dawant B., and Meltzer H. Occupancy of striatal and extrastriatal DA D2/3 receptors by olanzapine and haloperidol. Neuropsychopharmacology 30 (2005) 2283-2289
60. Grunder G., Landvogt C., Vernaleken, Buchholz H.-G., Ondracek J., and Siessmeier. The striatal and extrastriatal D2/3 receptor binding profile of clozapine in patients with schizophrenia. Neuropsychopharmacology 31 (2006) 1027-1035
61. Siessmeier T., Zhou Y., Buchholz H.G., Landvogt C., Vernaleken I., Piel M., et al. Parametric mapping of binding in human brain of D2 receptor ligands of different affinities. J Nucl Med 46 (2005) 964-972
62. Rohde G.K., Aldroubi A., and Dawant B.M. The adaptive bases algorithm for intensity-based nonridge image registration. IEEE Trans Med Imaging 22 (2003) 1470-1479
63. Forman S.D., Cohen J.D., Fitzgerald M., Eddy W.F., Mintun M.A., and Noll D.C. Improved assessment of significant activation in functional magnetic resonance imaging (fMRI): Use of a cluster-size threshold. Magn Reson Med 33 (1995) 636-647
64. Swanson L.W. The projections of the ventral tegmental area and adjacent regions: A combined fluorescent retrograde tracer and immunofluorescence study in the rat. Brain Res Bull 9 (1982) 321-353
65. Williams S.M., and Goldman-Rakic P.S. Widespread origin of the primates mesofrontal dopamine system. Cereb Cortex 8 (1998) 321-345
66. Kessler R.M., Ellis Jr. J.R., and Eden M. Analysis of emission tomographic scan data: Limitations imposed by resolution and background. J Comput Assist Tomogr 8 (1984) 514-522
67. Kessler R.M., Ansari M.S., Riccardi P., Li R., Jayathilake K., Dawant B., and Meltzer H. Occupancy of striatal and extrastriatal dopamine D2 receptors by clozapine and quetiapine. Neuropsychopharmacology 31 (2006) 1991-2001
68. 2/3 receptor binding in schizophrenia. Eur Arch Psychiatry Clin Neurosci 256 (2006) 382-387
69. 2 receptors. Synapse 34 (1999) 290-304
70. 123I]epidepride SPET. Eur J Nucl Med Mol Imaging 31 (2004) 644-654
71. Ichise M., Fujita M., Seibyl J.P., Verhoeff N.P., Baldwin R.M., Zoghbi S.S., et al. Graphical analysis and simplified quantification of striatal and extrastriatal dopamine D2 receptor binding with [123I]Epidepride SPECT. J Nucl Med 40 (1999) 1902-1912
72. Rieck R.W., Ansari M.S., Whetesell W.O., Detch A., and Kessler R.M. Distribution of dopamine D2-like receptors in the human thalamus: Autoradiographic and PET studies. Neuropsychopharmacology 29 (2004) 362-372
73. Alexander G.E., Crutcher M.D., and DeLong M.R. Basal ganglia- thalamocortical circuits: Parallel substrates for motor, oculomotor, "prefrontal" and limbic functions. Prog Brain Res 85 (1990) 119-146
74. Bubser M., and Deutch A. Thalamic paraventricular nucleus neurons collateralize to innervate the prefrontal cortex and nucleus accumbens. Brain Res 787 (1998) 304-310
75. Li S., and Kirouac G.J. Projections from the paraventricular nucleus of the thalamus to the forebrain, with special emphasis on the extended amygdala. J Comp Neurol 506 (2008) 263-287
76. Pakkenberg B. Pronounced reduction of total neuron number in mediodorsal thalamic nucleus and nucleus accumbens in schizophrenics. Arch Gen Psychiatry 47 (1990) 1023-1028
77. Byne W., Buchsbaum M.S., Mattiace L.A., Hazlett E.A., Kemether E., Elkhakem S.L., et al. Postmortem assessment of thalamic nuclear volumes in subjects with schizophrenia. Am J Psychiatry 159 (2002) 59-65
78. Gilbert A.R., Rosenberg D.R., Harenski K., Spencer S., Sweeney J.A., and Keshavan M.S. Thalamic volumes in patients with first-episode schizophrenia. Am J Psychiatry 158 (2001) 618-624
79. Kemether E.M., Buchsbaum M.S., Byne W., Haznedar M., Brickman A.M., Pltholi J., and Bloom R. Magnetic resonance imaging of mediodorsal, pulvinar, and centromedian nuclei of the thalamus in patients with schizophrenia. Arch Gen Psychiatry 60 (2003) 983-991
80. Oke A.F., and Adams R.N. Elevated thalamic dopamine: Possible link to sensory dysfunctions in schizophrenia. Schizophr Bull 13 (1987) 589-604
81. Liddle P.F., Friston K.J., Frith S.R., Hirsch T., Jones T., and Frackowiak S.R. Patterns of cerebral blood flow in schizophrenia. Br J Psychiatry 160 (1992) 179-186
82. Davison K., and Bagley C.R. Schizophrenia-like psychoses associated with organic disorders of the central nervous system: A review of literature. Br J Psychiatry Special issue 4 (1963) 113-182
83. Pilowsky L.S., Mulligan R.S., Acton P.D., Ell Pj Costa D.C., and Kerwin R.W. Limbic selectivity of clozapine. Lancet 350 (1997) 490-491
84. Stephenson C.M., Bigliani V., Jones H.M., Mulligan R.S., Acton PD Visvikis D., et al. Striatal and extra-striatal D(2)D(3) dopamine receptor occupancy by quetiapine in vivo. [9123]-epidepride single photon emission tomography (SPET) study. Br J Psychiatry 177 (2000) 408-415
85. Pearlson G.D., Wong D.F., Tune L.E., Ross C.A., Chase G.A., Links J.M., et al. In vivo D2 dopamaine receptor density in psychotic and nonpsychotic patients with bipolar disorder. Arch Gen Psychiatry 52 (1995) 471-477
86. Fehr C., Yakushev I., Homann N., Buchholz H.G., Landvogt C., and Deckers H. Association of low striatal dopamine D2 receptor availability with nicotine dependence similar to that seen with other drugs of abuse. Am J Psychiatry 165 (2008) 507-514
87. Nordström A.L., Olsson H., and Halldin C. A PET study of D2 dopamine receptor density at different phases of the menstrual Cycle. Psychiatry Res 83 (1998) 1-6
88. Wong D.F., Broussolle E.P., Wand G., Villemagne V., Dannals R.F., Links J.M., et al. In vivo measurement of dopamine receptors in human brain by positron emission tomography age and sex differences. Ann N Y Acad Sci 515 (1988) 203-214